Pear Therapeutics, Inc. (PEAR)
$0.0292
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | PEAR |
|---|---|
| Price | $0.0292 |
| Beta | 0.520 |
| Volume Avg. | 10.09M |
| Market Cap | 4.089M |
| Shares () | - |
| 52 Week Range | 0.009-6.74 |
| 1y Target Est | - |
| DCF Unlevered | PEAR DCF -> | |
|---|---|---|
| DCF Levered | PEAR LDCF -> | |
| ROE | 42.83% | Strong Buy |
| ROA | 26.05% | Buy |
| Operating Margin | - | |
| Debt / Equity | 122.96% | Buy |
| P/E | -0.08 | Neutral |
| P/B | 0.13 | Neutral |
Latest PEAR news
About
Download (Excel)Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA
Healthcare
Health Information Services
NASDAQ Capital Market
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.